Bottom line
Is HELX a good fund? The bottom line
HELX is an actively managed health care sector ETF from Franklin Templeton.
Its expense ratio is 0.5% — about $50 a year on every $10,000 invested, cheaper than 81% of health care sector funds we track.
It returned +25.9% over one year, −3.8% a year over five years (as of Dec 31, 2025, per its prospectus).
With $27.9 million in net assets and 63 holdings, its largest position is Guardant Health Inc (9.1%) and the top 10 make up 47.1% of the portfolio.
What stands out
- Low cost: cheaper than 81% of health care sector peers
What to watch
- 5-year return in the bottom quarter of its category
- Small fund ($27.9 million) — small funds are likelier to close
Updated Nov 19, 2026
What HELX invests in
Capital appreciation.
Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Funds investment theme of genomic advancements. The Fund invests predominantly in common stock. Companies relevant to the Funds investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly…
From the fund's prospectus (filed Jul 27, 2026).
HELX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| HELX | +25.9% | −3.8% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What HELX costs
On a $10,000 investment, HELX's 0.5% expense ratio costs about $50 a year. The prospectus estimates $629 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
HELX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Guardant Health Inc GH | 9.09% |
| 2 | Natera Inc NTRA | 7.46% |
| 3 | Krystal Biotech Inc KRYS | 6.33% |
| 4 | Ligand Pharmaceuticals Inc LGND | 4.62% |
| 5 | Adaptive Biotechnologies Corp ADPT | 3.99% |
| 6 | United Therapeutics Corp UTHR | 3.51% |
| 7 | Bridgebio Pharma Inc BBIO | 3.50% |
| 8 | Eli Lilly & Company LLY | 2.95% |
| 9 | Twist Bioscience Corp TWST | 2.85% |
| 10 | Vertex Pharmaceuticals Inc VRTX | 2.75% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 47.1% of the fund. See all top 25 holdings and asset mix →